On the stock market since 2022, it operates in the world of health and science. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
An average decline of 9% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Profit per Sale: Right now the product sells for less than it costs to make; every sale deepens the loss.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
Sales run at $843K a year. A small number, but proof the product has real buyers.
A loss of $6.0M against $843K in annual sales.
The stock sits at $0.0001. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
This stock swings about 233.5 times as much as the market average. Big rallies — and big drops — can both happen fast.
On our five-subject report card, SXHHF sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: SXHHF is a high-risk stock — not yet profitable, and its future rides on its product catching on.